We're still determining how we will navigate these cuts. Again, we are looking to work with government stakeholders in order to potentially alleviate the extent of these cuts here. We are in the process of launching a competition at BioCanRx, in addition to meeting with government stakeholders and working with a number of other not-for-profit stakeholders and charities in the cancer space to see how we can mitigate these cuts to BioCanRx.
It's still early days as we try to determine the overall impact of the cuts. The worst-case scenario is that there could be projects, potentially, that are not funded in that very critical development space. Ultimately, the impact could be that a research team isn't able to file with Health Canada for a future clinical trial application because that funding wasn't available to fund the development.
